IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells

Hyunkeun Song, Kyung Eun Kim, Daeyoung Hur, Jong Seok Lim, Young Yang, Byung Joo Cho, Cherl hyun Kim, Tae Sung Kim, Saic Bang, Wang Jae Lee, Hyunjeong Park, Dae Ho Cho

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Expression of UL16-binding proteins (ULBPs) has been reported in various cancers, such as leukemia and melanoma, and also in some other cancer cell lines. However, the factors that modulate the expression of ULBPs are not well defined. In this study, we investigated the effects of IL-18 on the expression of NKG2D ligands in leukemia cells. IL-18 treatment increased ULBP2 expression in leukemia cells at the mRNA and protein levels. In addition, PD98059 (an ERK1/2 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated IL-18-induced ULBP2 expression in a dose-dependent manner. We observed that ERK1/2 and JNK MAPK phosphorylation increased upon treatment with IL-18. IL-18 elevated CD107a expression in cancer cells and increased the cytotoxic activity of NK cells; therefore, we propose that IL-18 increases the susceptibility of target cells by inducing surface expression of ULBP2. Taken together, these findings suggest that IL-18 may play a critical role in regulating ULBP2 expression via the ERK1/2 and JNK MAPK pathways in leukemia cells.

Original languageEnglish
Pages (from-to)103-107
Number of pages5
JournalImmunology Letters
Volume120
Issue number1-2
DOIs
Publication statusPublished - 2008 Sep 30

Fingerprint

Interleukin-18
Leukemia
Carrier Proteins
Neoplasms
MAP Kinase Signaling System
Natural Killer Cells
Melanoma
Phosphorylation
Ligands
Cell Line
Messenger RNA

Keywords

  • IL-18
  • Natural killer cells
  • NKG2D
  • Tumor immunity
  • ULBP

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells. / Song, Hyunkeun; Kim, Kyung Eun; Hur, Daeyoung; Lim, Jong Seok; Yang, Young; Cho, Byung Joo; Kim, Cherl hyun; Kim, Tae Sung; Bang, Saic; Lee, Wang Jae; Park, Hyunjeong; Cho, Dae Ho.

In: Immunology Letters, Vol. 120, No. 1-2, 30.09.2008, p. 103-107.

Research output: Contribution to journalArticle

Song, H, Kim, KE, Hur, D, Lim, JS, Yang, Y, Cho, BJ, Kim, CH, Kim, TS, Bang, S, Lee, WJ, Park, H & Cho, DH 2008, 'IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells', Immunology Letters, vol. 120, no. 1-2, pp. 103-107. https://doi.org/10.1016/j.imlet.2008.07.007
Song, Hyunkeun ; Kim, Kyung Eun ; Hur, Daeyoung ; Lim, Jong Seok ; Yang, Young ; Cho, Byung Joo ; Kim, Cherl hyun ; Kim, Tae Sung ; Bang, Saic ; Lee, Wang Jae ; Park, Hyunjeong ; Cho, Dae Ho. / IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells. In: Immunology Letters. 2008 ; Vol. 120, No. 1-2. pp. 103-107.
@article{49b9d94749484c199db2e09a21516de9,
title = "IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells",
abstract = "Expression of UL16-binding proteins (ULBPs) has been reported in various cancers, such as leukemia and melanoma, and also in some other cancer cell lines. However, the factors that modulate the expression of ULBPs are not well defined. In this study, we investigated the effects of IL-18 on the expression of NKG2D ligands in leukemia cells. IL-18 treatment increased ULBP2 expression in leukemia cells at the mRNA and protein levels. In addition, PD98059 (an ERK1/2 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated IL-18-induced ULBP2 expression in a dose-dependent manner. We observed that ERK1/2 and JNK MAPK phosphorylation increased upon treatment with IL-18. IL-18 elevated CD107a expression in cancer cells and increased the cytotoxic activity of NK cells; therefore, we propose that IL-18 increases the susceptibility of target cells by inducing surface expression of ULBP2. Taken together, these findings suggest that IL-18 may play a critical role in regulating ULBP2 expression via the ERK1/2 and JNK MAPK pathways in leukemia cells.",
keywords = "IL-18, Natural killer cells, NKG2D, Tumor immunity, ULBP",
author = "Hyunkeun Song and Kim, {Kyung Eun} and Daeyoung Hur and Lim, {Jong Seok} and Young Yang and Cho, {Byung Joo} and Kim, {Cherl hyun} and Kim, {Tae Sung} and Saic Bang and Lee, {Wang Jae} and Hyunjeong Park and Cho, {Dae Ho}",
year = "2008",
month = "9",
day = "30",
doi = "10.1016/j.imlet.2008.07.007",
language = "English",
volume = "120",
pages = "103--107",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells

AU - Song, Hyunkeun

AU - Kim, Kyung Eun

AU - Hur, Daeyoung

AU - Lim, Jong Seok

AU - Yang, Young

AU - Cho, Byung Joo

AU - Kim, Cherl hyun

AU - Kim, Tae Sung

AU - Bang, Saic

AU - Lee, Wang Jae

AU - Park, Hyunjeong

AU - Cho, Dae Ho

PY - 2008/9/30

Y1 - 2008/9/30

N2 - Expression of UL16-binding proteins (ULBPs) has been reported in various cancers, such as leukemia and melanoma, and also in some other cancer cell lines. However, the factors that modulate the expression of ULBPs are not well defined. In this study, we investigated the effects of IL-18 on the expression of NKG2D ligands in leukemia cells. IL-18 treatment increased ULBP2 expression in leukemia cells at the mRNA and protein levels. In addition, PD98059 (an ERK1/2 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated IL-18-induced ULBP2 expression in a dose-dependent manner. We observed that ERK1/2 and JNK MAPK phosphorylation increased upon treatment with IL-18. IL-18 elevated CD107a expression in cancer cells and increased the cytotoxic activity of NK cells; therefore, we propose that IL-18 increases the susceptibility of target cells by inducing surface expression of ULBP2. Taken together, these findings suggest that IL-18 may play a critical role in regulating ULBP2 expression via the ERK1/2 and JNK MAPK pathways in leukemia cells.

AB - Expression of UL16-binding proteins (ULBPs) has been reported in various cancers, such as leukemia and melanoma, and also in some other cancer cell lines. However, the factors that modulate the expression of ULBPs are not well defined. In this study, we investigated the effects of IL-18 on the expression of NKG2D ligands in leukemia cells. IL-18 treatment increased ULBP2 expression in leukemia cells at the mRNA and protein levels. In addition, PD98059 (an ERK1/2 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated IL-18-induced ULBP2 expression in a dose-dependent manner. We observed that ERK1/2 and JNK MAPK phosphorylation increased upon treatment with IL-18. IL-18 elevated CD107a expression in cancer cells and increased the cytotoxic activity of NK cells; therefore, we propose that IL-18 increases the susceptibility of target cells by inducing surface expression of ULBP2. Taken together, these findings suggest that IL-18 may play a critical role in regulating ULBP2 expression via the ERK1/2 and JNK MAPK pathways in leukemia cells.

KW - IL-18

KW - Natural killer cells

KW - NKG2D

KW - Tumor immunity

KW - ULBP

UR - http://www.scopus.com/inward/record.url?scp=50449084622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50449084622&partnerID=8YFLogxK

U2 - 10.1016/j.imlet.2008.07.007

DO - 10.1016/j.imlet.2008.07.007

M3 - Article

VL - 120

SP - 103

EP - 107

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

IS - 1-2

ER -